EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CAR-T cell therapy: a game-changer in cancer treatment and beyond

Kumar Utkarsh, Namita Srivastava, Sachin Kumar, Azhar Khan, Gunjan Dagar, Mukesh Kumar, Mayank Singh, Shabirul Haque

Clinical and Translational Oncology · 20.01.2024 · 26 (6) · 1300-1318

DOI: 10.1007/s12094-023-03368-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, online erschienen am 20.01.2024. Verfasst von Kumar Utkarsh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Biotechnology, Shoolini University, Solan, Himachal Pradesh, 173229, India. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 172 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, cancer has become one of the primary causes of mortality, approximately 10 million deaths worldwide each year. The most advanced, chimeric antigen receptor (CAR) T cell immunotherapy has turned out as a promising treatment for cancer. CAR-T cell therapy involves the genetic modification of T cells obtained from the patient's blood, and infusion back to the patients. CAR-T cell immunotherapy has led to a significant improvement in the remission rates of hematological cancers. CAR-T cell therapy presently limited to hematological cancers, there are ongoing efforts to develop additional CAR constructs such as bispecific CAR, tandem CAR, inhibitory CAR, combined antigens, CRISPR gene-editing, and nanoparticle delivery. With these advancements, CAR-T cell therapy holds promise concerning potential to improve upon traditional cancer treatments such as chemotherapy and radiation while reducing associated toxicities. This review covers recent advances and advantages of CAR-T cell immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveReceptors, Chimeric AntigenNeoplasmsHumansHematologic NeoplasmsGene EditingT-Lymphocytes

Stichwörter der Autor:innen

Bispecific CARCAR-T cell therapyCancer treatmentHematologic cancersImmunotherapyInhibitory CARTumor antigens

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Microbiology and Biotechnology, Shoolini University, Solan, Himachal Pradesh, 173229, India.
  • Faculty of Applied Science and Biotechnology, Shoolini University, Solan, Himachal Pradesh, 173229, India.
  • Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
  • Department of Autoimmune Diseases, Feinstein Institute for Medical Research, Northwell Health, 350, Community Drive, Manhasset, NY, 11030, USA. shaque@northwell.edu.

Zitieren

APA

Utkarsh, K., Srivastava, N., Kumar, S., Khan, A., Dagar, G., Kumar, M., Singh, M., & Haque, S. (2024). CAR-T cell therapy: a game-changer in cancer treatment and beyond. Clinical and Translational Oncology, 26(6), 1300-1318. https://doi.org/10.1007/s12094-023-03368-2

Vancouver

Utkarsh K, Srivastava N, Kumar S, Khan A, Dagar G, Kumar M, et al. CAR-T cell therapy: a game-changer in cancer treatment and beyond. Clinical and Translational Oncology. 2024;26(6):1300-1318. doi:10.1007/s12094-023-03368-2

BibTeX
@article{Utkarsh2024,
  author = {Utkarsh, Kumar and Srivastava, Namita and Kumar, Sachin and Khan, Azhar and Dagar, Gunjan and Kumar, Mukesh and Singh, Mayank and Haque, Shabirul},
  title = {CAR-T cell therapy: a game-changer in cancer treatment and beyond},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  volume = {26},
  number = {6},
  pages = {1300--1318},
  doi = {10.1007/s12094-023-03368-2}
}
Kostenlos starten →